SciSparc Advances Phase IIb Trial for Tourette Syndrome Treatment in Germany
Event summary
- SciSparc's subsidiary NeuroThera has initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-110, a cannabinoid-based treatment for Tourette Syndrome in adults.
- The trial follows regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee.
- SCI-110 combines dronabinol with palmitoylethanolamide to reduce tics and comorbid symptoms while minimizing side effects.
- Previous Phase IIa results showed an average tic reduction of 21% as measured by the Yale Global Tic Severity Scale.
The big picture
SciSparc’s advancement of the Phase IIb trial for SCI-110 underscores the growing interest in cannabinoid-based therapies for neurological disorders. The initiation of multiple international trial sites highlights the strategic importance of global collaboration in clinical development. With limited treatment options currently available for adult Tourette Syndrome, successful outcomes from this trial could significantly impact the therapeutic landscape and market dynamics.
What we're watching
- Trial Execution
- The pace at which patient enrollment and randomization proceed across the three trial sites will determine the timeline for efficacy and safety data.
- Regulatory Pathway
- Whether the positive Phase IIa results translate into successful Phase IIb outcomes, paving the way for future regulatory approvals.
- Market Potential
- How SCI-110's novel approach could position it as a leading treatment option in the underserved adult Tourette Syndrome market.
Related topics